Value-based health care: issues for pharmaceutical companies
Michael Lampert, Ropes & Gray health care partner, discusses issues facing pharmaceutical companies with the move towards value-based health care models.
Trending Similar Videos
Health care M&A
John Chesley, a health care partner, discusses M&A deal-making in the industry and the impact of value-based payment models. He also outlines a new Bloomberg BNA portfolio on M&A transactions that he co-authored. More info at http://bit.ly/2rMbNVE.
FCPA enforcement in the Trump administration
Alex Rene, co-chair of Ropes & Gray’s anti-corruption and international risk practice, discusses likely FCPA enforcement activity under the Trump administration.
Value-based health care: data & technology
Ira Parghi, Ropes & Gray health care counsel, discusses the increasing role that data and technology will play in a value-based health care world.
FCPA Pilot Program
Ryan Rohlfsen, Ropes & Gray government enforcement partner, analyzes the first year of the U.S. Department of Justice’s FCPA Pilot Program.
Thomas Holden, Ropes & Gray securities & public companies partner, analyzes the benefits of dual-track IPOs, particularly in choppy markets, and discusses considerations in managing a dual-track process.
Value-based health care: private equity investors
Deborah Gersh, Ropes & Gray health care partner, discusses considerations for private equity companies investing in the value-based health care space.